Short answer
Annexon, Inc. (ANNX) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$55M
- −57.7% YoY · −11.7% QoQ
- EPS (diluted)
- −$0.37
- −48.0% YoY · −8.8% QoQ
Source: XBRL data from the Annexon, Inc. (ANNX) Q3 2025 10-Q on SEC EDGAR. USD.
Annexon, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly triggered risk identified; section primarily carries forward risks from the prior 10-K
- Capital resources $188.7 million at September 30, 2025, expected to fund planned operations into late first quarter 2027
- ARCHER II Phase 3 program may require additional capital and faces FDA data-acceptance uncertainty
- Two FDA-approved GA therapies may hinder vonaprument trial recruitment
- Net loss $158.4 million for nine months ended September 30, 2025; accumulated deficit $869.1 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Annexon, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.